Recruitment

Recruitment Status
Recruiting

Inclusion Criteria

Neutrophil count >= 1.5 K/mm^3
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
Leukocytes >= 3,000/mcL
...
Neutrophil count >= 1.5 K/mm^3
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
Leukocytes >= 3,000/mcL
Endometrial cancer
Hemoglobin >= 9 g/dL
Malignant pleural mesothelioma
Triple-negative breast cancer (Her2/neu-negative, estrogen receptor [ER]/progesterone receptor [PR]-negative breast cancer)
Availability of archival FFPE tissue
Patients with histologically confirmed advanced or unresectable urothelial carcinoma are eligible
Total bilirubin =< 2 mg/dL
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 x institutional upper limit of normal (ULN)
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional classification. To be eligible for this trial, patients should be class 2B or better
Platelets >= 100 K/mm^3
Biliary tract cancer
Esophageal and gastric cancers
Creatinine clearance >= 40 mL/min OR glomerular filtration rate (GFR) >= 60 mL/min/1.73 m^2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m^2
UC
The histology should be predominantly urothelial (>= 50% of sample evaluated contains urothelial histology)
Ovarian cancer
Non-small cell lung cancer (NSCLC)
Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy
Prior cisplatin exposure of < 300 mg/m^2, with last cisplatin treatment > 6 months prior to enrollment is permitted
Cervical cancer
Small cell lung cancer
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
The effects of BAY 1895344, cisplatin, and gemcitabine on the developing human fetus are unknown. For this reason and because deoxyribonucleic acid (DNA)-damage response inhibitors agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and for 6 months after completion of BAY 1895344 administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of BAY 1895344 administration
Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible
Head and neck cancer
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
Prior immune checkpoint inhibitor therapy is permitted
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
Penile cancer
Prior treatment with PARP inhibitors is permitted

Exclusion Criteria

Life expectancy < 6 weeks by investigator assessment
Patients receiving any medications that are substrates of CYP3A4 with a narrow therapeutic window, or strong inhibitors/inducers of CYP3A4 are ineligible, if they cannot be transferred to alternative medication. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Pregnant women are excluded from this study because BAY 1895344 as a DNA-damage response inhibitor, cisplatin, and gemcitabine may have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with BAY 1895344 breastfeeding should be discontinued if the mother is treated with BAY 1895344 and for 4 months after end of treatment. These potential risks may also apply to other agents used in this study
...
Life expectancy < 6 weeks by investigator assessment
Patients receiving any medications that are substrates of CYP3A4 with a narrow therapeutic window, or strong inhibitors/inducers of CYP3A4 are ineligible, if they cannot be transferred to alternative medication. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Pregnant women are excluded from this study because BAY 1895344 as a DNA-damage response inhibitor, cisplatin, and gemcitabine may have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with BAY 1895344 breastfeeding should be discontinued if the mother is treated with BAY 1895344 and for 4 months after end of treatment. These potential risks may also apply to other agents used in this study
Must NOT have had prior treatment with ATR inhibitor (prior BAY1895344 or other investigational ATR inhibitors), or current treatment with any other investigational agents
Patients with uncontrolled intercurrent illness
Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
History of prior malignancy requiring intervention in the past 3 years, except for cutaneous malignancies that require resection, such as squamous cell carcinoma, basal cell carcinoma, or cutaneous melanomas
Significant peripheral neuropathy or sensorineural hearing loss (< grade 1 by Common Terminology Criteria for Adverse Events [CTCAE])
History of allergic reactions attributed to compounds of similar chemical or biologic composition to BAY 1895344 or other agents used in study
Patients with psychiatric illness/social situations that would limit compliance with study requirements

Summary

Conditions
  • Advanced Head and Neck Carcinoma
  • Advanced Bile Duct Carcinoma
  • Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8
  • Stage III Penile Cancer AJCC v8
  • Stage IV Intrahepatic Bile Duct Cancer AJCC v8
  • Anatomic Stage IV Breast Cancer AJCC v8
  • Clinical Stage IVB Gastric Cancer AJCC v8
  • Stage IIIA Ovarian Cancer AJCC v8
  • Stage IIIB Distal Bile Duct Cancer AJCC v8
  • Triple-Negative Breast Carcinoma
  • Advanced Breast Carcinoma
  • Advanced Cervical Carcinoma
  • Advanced Endometrial Carcinoma
  • Stage III Cervical Cancer AJCC v8
  • Stage III Ovarian Cancer AJCC v8
  • Anatomic Stage IIIA Breast Cancer AJCC v8
  • Stage III Distal Bile Duct Cancer AJCC v8
  • Advanced Esophageal Carcinoma
  • Advanced Gastric Carcinoma
  • Prognostic Stage III Breast Cancer AJCC v8
  • Clinical Stage IV Gastric Cancer AJCC v8
  • Stage IVB Lung Cancer AJCC v8
  • Pathologic Stage IIIC Gastric Cancer AJCC v8
  • Advanced Lung Non-Small Cell Carcinoma
  • Anatomic Stage IIIC Breast Cancer AJCC v8
  • Prognostic Stage IIIA Breast Cancer AJCC v8
  • Stage IVA Lung Cancer AJCC v8
  • Stage IIIB Ovarian Cancer AJCC v8
  • Stage III Pleural Malignant Mesothelioma AJCC v8
  • Stage IVB Ovarian Cancer AJCC v8
  • Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8
  • Pathologic Stage IIIA Gastric Cancer AJCC v8
  • Stage IV Distal Bile Duct Cancer AJCC v8
  • Stage IIIA Distal Bile Duct Cancer AJCC v8
  • Advanced Penile Carcinoma
  • Stage IIIA Pleural Malignant Mesothelioma AJCC v8
  • Stage IV Ovarian Cancer AJCC v8
  • Stage IIIB Penile Cancer AJCC v8
  • Stage IIIB Pleural Malignant Mesothelioma AJCC v8
  • Stage IVA Cervical Cancer AJCC v8
  • Stage IV Penile Cancer AJCC v8
  • Stage IIIA Lung Cancer AJCC v8
  • Stage IIIC Ovarian Cancer AJCC v8
  • Clinical Stage IVA Gastric Cancer AJCC v8
  • Stage III Lung Cancer AJCC v8
  • Prognostic Stage IIIC Breast Cancer AJCC v8
  • Stage III Intrahepatic Bile Duct Cancer AJCC v8
  • Pathologic Stage IV Gastric Cancer AJCC v8
  • Advanced Lung Small Cell Carcinoma
  • Stage IIIA2 Ovarian Cancer AJCC v8
  • Stage IIIA1 Ovarian Cancer AJCC v8
  • Stage IV Cervical Cancer AJCC v8
  • Advanced Urothelial Carcinoma
  • Anatomic Stage III Breast Cancer AJCC v8
  • Stage IV Lung Cancer AJCC v8
  • Stage IVB Cervical Cancer AJCC v8
  • Unresectable Urothelial Carcinoma
  • Stage IIIA Penile Cancer AJCC v8
  • Stage IIIC Lung Cancer AJCC v8
  • Stage IV Pleural Malignant Mesothelioma AJCC v8
  • Stage IVA Ovarian Cancer AJCC v8
  • Advanced Malignant Solid Neoplasm
  • Anatomic Stage IIIB Breast Cancer AJCC v8
  • Prognostic Stage IIIB Breast Cancer AJCC v8
  • Prognostic Stage IV Breast Cancer AJCC v8
  • Stage IIIB Cervical Cancer AJCC v8
  • Stage IIIA Cervical Cancer AJCC v8
  • Advanced Pleural Malignant Mesothelioma
  • Advanced Ovarian Carcinoma
  • Clinical Stage III Gastric Cancer AJCC v8
  • Pathologic Stage IIIB Gastric Cancer AJCC v8
  • Stage IIIB Lung Cancer AJCC v8
  • Pathologic Stage III Gastric Cancer AJCC v8
Type
Interventional
Phase
Phase 1
Design
  • Allocation: Non-Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

PRIMARY OBJECTIVES: I. To establish the safety and tolerability of the combination of cisplatin + ATR kinase inhibitor BAY1895344 (BAY 1895344) in patients with advanced solid tumors. II. To establish the safety and tolerability of the combination of cisplatin + gemcitabine + BAY 1895344 in patients...

PRIMARY OBJECTIVES: I. To establish the safety and tolerability of the combination of cisplatin + ATR kinase inhibitor BAY1895344 (BAY 1895344) in patients with advanced solid tumors. II. To establish the safety and tolerability of the combination of cisplatin + gemcitabine + BAY 1895344 in patients with advanced solid tumors with an emphasis on urothelial carcinoma (UC). III. To establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of cisplatin + BAY 1895344 and cisplatin + gemcitabine + BAY 1895344. SECONDARY OBJECTIVES: I. To observe and record anti-tumor activity. II. To evaluate the pharmacokinetic profile of BAY 1895344 (in the doublet and triplet combinations) and gemcitabine (in the triplet) in combination with cisplatin. III. To further evaluate the toxicity of the combination of cisplatin + gemcitabine + BAY 1895344 in patients with UC. IV. To evaluate preliminary efficacy observed with cisplatin + BAY 1895344 and cisplatin + gemcitabine + BAY 1895344 in patients with advanced solid tumors, including UC. V. To evaluate the association between ATM expression by immunohistochemical staining and responses to therapy. EXPLORATORY OBJECTIVES: I. To evaluate the responses to therapy using whole exome sequencing (WES) and messenger ribonucleic acid (RNA) sequencing (RNA Seq) analysis of archival formalin fixed paraffin embedded (FFPE) tissue. II. To correlate drug exposure with response and/or toxicity. OUTLINE: This is a dose-escalation study of BAY 1895344. Patients are assigned to 1 of 2 arms. ARM I (DOUBLET COMBINATION): Patients receive cisplatin intravenously (IV) over 1-2 hours on day 1, and BAY 1895344 orally (PO) twice daily (BID) on days 2 and 9. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. ARM II (TRIPLET COMBINATION): Patients receive cisplatin IV over 1-2 hours on day 1, gemcitabine IV over 30 minutes on days 1 and 8, and BAY 1895344 PO BID on days 2 and 9. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days, then every 3 months thereafter.

Inclusion Criteria

Neutrophil count >= 1.5 K/mm^3
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
Leukocytes >= 3,000/mcL
...
Neutrophil count >= 1.5 K/mm^3
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
Leukocytes >= 3,000/mcL
Endometrial cancer
Hemoglobin >= 9 g/dL
Malignant pleural mesothelioma
Triple-negative breast cancer (Her2/neu-negative, estrogen receptor [ER]/progesterone receptor [PR]-negative breast cancer)
Availability of archival FFPE tissue
Patients with histologically confirmed advanced or unresectable urothelial carcinoma are eligible
Total bilirubin =< 2 mg/dL
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 x institutional upper limit of normal (ULN)
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional classification. To be eligible for this trial, patients should be class 2B or better
Platelets >= 100 K/mm^3
Biliary tract cancer
Esophageal and gastric cancers
Creatinine clearance >= 40 mL/min OR glomerular filtration rate (GFR) >= 60 mL/min/1.73 m^2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m^2
UC
The histology should be predominantly urothelial (>= 50% of sample evaluated contains urothelial histology)
Ovarian cancer
Non-small cell lung cancer (NSCLC)
Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy
Prior cisplatin exposure of < 300 mg/m^2, with last cisplatin treatment > 6 months prior to enrollment is permitted
Cervical cancer
Small cell lung cancer
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
The effects of BAY 1895344, cisplatin, and gemcitabine on the developing human fetus are unknown. For this reason and because deoxyribonucleic acid (DNA)-damage response inhibitors agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and for 6 months after completion of BAY 1895344 administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of BAY 1895344 administration
Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible
Head and neck cancer
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
Prior immune checkpoint inhibitor therapy is permitted
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
Penile cancer
Prior treatment with PARP inhibitors is permitted

Exclusion Criteria

Life expectancy < 6 weeks by investigator assessment
Patients receiving any medications that are substrates of CYP3A4 with a narrow therapeutic window, or strong inhibitors/inducers of CYP3A4 are ineligible, if they cannot be transferred to alternative medication. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Pregnant women are excluded from this study because BAY 1895344 as a DNA-damage response inhibitor, cisplatin, and gemcitabine may have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with BAY 1895344 breastfeeding should be discontinued if the mother is treated with BAY 1895344 and for 4 months after end of treatment. These potential risks may also apply to other agents used in this study
...
Life expectancy < 6 weeks by investigator assessment
Patients receiving any medications that are substrates of CYP3A4 with a narrow therapeutic window, or strong inhibitors/inducers of CYP3A4 are ineligible, if they cannot be transferred to alternative medication. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
Pregnant women are excluded from this study because BAY 1895344 as a DNA-damage response inhibitor, cisplatin, and gemcitabine may have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with BAY 1895344 breastfeeding should be discontinued if the mother is treated with BAY 1895344 and for 4 months after end of treatment. These potential risks may also apply to other agents used in this study
Must NOT have had prior treatment with ATR inhibitor (prior BAY1895344 or other investigational ATR inhibitors), or current treatment with any other investigational agents
Patients with uncontrolled intercurrent illness
Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
History of prior malignancy requiring intervention in the past 3 years, except for cutaneous malignancies that require resection, such as squamous cell carcinoma, basal cell carcinoma, or cutaneous melanomas
Significant peripheral neuropathy or sensorineural hearing loss (< grade 1 by Common Terminology Criteria for Adverse Events [CTCAE])
History of allergic reactions attributed to compounds of similar chemical or biologic composition to BAY 1895344 or other agents used in study
Patients with psychiatric illness/social situations that would limit compliance with study requirements

Locations

Madison, Wisconsin, 53792
Sacramento, California, 95817
Bethesda, Maryland, 20892
Columbus, Ohio, 43210
Pittsburgh, Pennsylvania, 15232
...
Madison, Wisconsin, 53792
Sacramento, California, 95817
Bethesda, Maryland, 20892
Columbus, Ohio, 43210
Pittsburgh, Pennsylvania, 15232
Bethesda, Maryland, 20892

Tracking Information

NCT #
NCT04491942
Collaborators
Not Provided
Investigators
  • Principal Investigator: Mamta Parikh City of Hope Comprehensive Cancer Center LAO
  • Mamta Parikh City of Hope Comprehensive Cancer Center LAO